UTI Q3 Earnings Miss, Full-Year Guidance Slashed as Growth Costs Bite
UTI sits 32% above its 52-week low of $21.29 on elevated volume (5.3× avg).
Summary
UTI's Q3 net income plunged 79% YoY to $2.3M on $218.9M revenue. Full-year guidance was cut across the board as growth investments pressure margins. Restructuring charges and a new insider trading plan add to the negative tone.
Key Events · Earnings and Guidance · UTI
-
Q3 Earnings Miss
Revenue of $218.9M (+7.2% YoY) but net income fell to $2.3M ($0.04/share) from $10.7M ($0.20/share) a year ago, as operating expenses grew faster than revenue.
-
Full-Year Guidance Slashed
Management cut full-year guidance for revenue, EBITDA, new student starts, and capex. The prior outlook had already been lowered; this further reduction signals worsening cost pressures and slower growth.
-
Restructuring Initiated
A $1.1M restructuring charge was taken for Phase I of a multi-year plan to simplify operations and improve student acquisition. Additional phases are planned over the next three years.
-
Insider Selling Context
The guidance cut follows a wave of insider selling over the past 90 days, including $3.9M by the CEO and a $173M block sale by a major shareholder. The Chairman also adopted a new 10b5-1 plan for up to 64,210 shares.
Analysis · UTI · Trade & Services
Universal Technical Institute reported a sharp drop in profitability for the June quarter, with net income falling to $2.3 million from $10.7 million a year ago despite 7% revenue growth. The company cut full-year guidance across revenue, EBITDA, student starts, and capex, citing heavy spending on new campus openings and program expansions. A $1.1 million restructuring charge signals management is now actively cutting costs. Against a backdrop of heavy insider selling over the past 90 days, the guidance cut and margin compression raise questions about the payoff timeline for the aggressive growth strategy.
At the time of this filing, UTI was trading at $28.00 on NYSE in the Trade & Services sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $21.29 to $51.34. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.